Product information and disease descriptionPlace of product in therapyDisease description
Definition and etiology
8 evidence topics · 5 sources
Guideline definition: autosomal recessive neurovisceral lysosomal disorder
“Statement #1: NPC is a progressive and life‐limiting autosomal recessive, neurovisceral lysosomal disorder caused by pathological variants in either NPC1 or NPC2.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Variants in these genes are associated with abnormal endosomal‐lysosomal trafficking, resulting in the accumulation of unesterified cholesterol and other lipids in the lysosomes.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Disease onset varies, ranging from antenatally to throughout the lifespan.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Genetic basis and diagnostic definition
Autosomal recessive inheritance and recurrence risk
Genetic etiology and clinical forms by age at onset
“Niemann-Pick disease type C (NPC) is an autosomal recessive disorder caused by pathogenic variants in NPC1 (OMIM 257220, HGNC:7897) or NPC2 (OMIM 607625, HGNC:14537)” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“The infantile-onset form of NPC is characterized by cholestatic liver disease, hepatosplenomegaly, and pulmonary infiltrates, whereas later presentations include progressive neurologic symptoms, including cognitive impairment, cerebellar ataxia, psychiatric manifestations, and seizures, in addition to visceral disease.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Definition of infantile-onset NPC: sponsor statement
Classification by age at onset of neurological manifestations
“Nevertheless, NPC is best classified according to the age at onset of neurological manifestations, as this correlates with prognosis, as follows:” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Pre/perinatal (< 2 months)” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Early infantile (2 months–2 years)” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Late infantile (2–6 years)” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Juvenile (6–16 years)” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Adult (> 16 years)” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Alternative onset-category thresholds in a registry-based survival study
“Miglustat‐treated and untreated patients overall and within sub‐groups according to age‐at‐neurological‐onset, that is, early infantile‐onset (<2 years), late infantile‐onset (2 to <6 years), juvenile‐onset (6 to <15 years), and adolescent/adult‐onset (≥15 years) were analysed and compared.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote